In a nutshell This study wanted to see how well the medication afatinib (Giotrif) works in real-life settings, outside of clinical trials in patients with advanced non-small cell lung cancer (NSCLC). The study found that patients treated with afatinib had a good response rate and survival. Some background There are many...
Read More
In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...
Read More
In a nutshell This study examined the effectiveness and safety of adding durvalumab (Imfinzi) to platinum-etoposide to treat patients with small-cell lung carcinoma (SCLC). The authors found that durvalumab was well-tolerated and improved survival outcomes. Some background Small cell lung carcinoma (SCLC) is a type of lung cancer that...
Read More
In a nutshell This study compared the effectiveness and safety of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus chemotherapy for non-small cell lung cancer (NSCLC). The authors concluded that this combination treatment improved survival outcomes more than chemotherapy. Some background Treatment for NSCLC often includes chemotherapy or...
Read More
In a nutshell This study evaluated whether zoledronate (Zometa) combined with TKI therapy is more effective than TKI therapy alone for patients with non-small cell lung cancer (NSCLC) spread to the bones. This study concluded that adding zoledronate to TKI therapy improved survival outcomes for these patients. Some background NSCLC is the most common...
Read More
In a nutshell This study investigated whether adding chemotherapy agents to gefitinib (Iressa) improved outcomes for patients with advanced non-small cell lung cancer (NSCLC). This study found that this combination improved survival but increased side effects for these patients. Some background The gene for epidermal growth factor receptor...
Read More
In a nutshell This phase 1/2 study will investigate the safety of a new drug, BMS-986156, combined with ipilimumab (Yervoy), nivolumab (Opdivo) and radiotherapy in advanced lung cancer (LC). The main outcomes will be the rate of dose-limiting side effects and response to treatment. This trial is recruiting in Texas, US. The details...
Read More
In a nutshell This study investigated the safety and effectiveness of pembrolizumab (Keytruda) in patients of 75 years or older with PD-L1 positive non-small-cell-lung cancer (NSCLC). Authors concluded that pembrolizumab improved overall survival and was safer than chemotherapy in these patients. Some background Lung cancer is one of the most common...
Read More
In a nutshell This study examined how effective additional chemotherapy alongside chemo-radiotherapy is in patients with locally advanced non-small cell lung cancer. The study found that additional chemotherapy did not bring survival benefits in these patients. Some background Non-small cell lung cancer (NSCLC) can be difficult to treat. There are a...
Read More
In a nutshell This study investigated if atezolizumab (Tecentriq) combined with chemotherapy (CT) is effective in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC). They found that this treatment improved survival in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common lung cancer...
Read More
In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with non-small cell lung cancer (NSCLC) receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety and effectiveness of APL-101 in advanced non-small cell lung cancer (NSCLC). The main outcomes will be to determine the recommended phase 2 dose (RP2D) and the response rate (RR) in phase 2. This trial is recruiting at multiple locations across the US. The details...
Read More
